Verona Pharma Current Valuation vs. Gross Profit

VRNA Stock  USD 41.42  2.16  5.50%   
Based on the key profitability measurements obtained from Verona Pharma's financial statements, Verona Pharma PLC may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Verona Pharma's ability to earn profits and add value for shareholders. As of December 13, 2024, Price To Sales Ratio is expected to decline to 4,122. In addition to that, Days Sales Outstanding is expected to decline to 8,081. At present, Verona Pharma's Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 11.9 M, whereas Accumulated Other Comprehensive Income is projected to grow to (3.9 M).
For Verona Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Verona Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Verona Pharma PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Verona Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Verona Pharma PLC over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.00)
Revenue Per Share
0.07
Return On Assets
(0.28)
Return On Equity
(0.78)
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Verona Pharma PLC Gross Profit vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Verona Pharma's current stock value. Our valuation model uses many indicators to compare Verona Pharma value to that of its competitors to determine the firm's financial worth.
Verona Pharma PLC is rated below average in current valuation category among its peers. It is rated below average in gross profit category among its peers . The ratio of Current Valuation to Gross Profit for Verona Pharma PLC is about  27,288 . At present, Verona Pharma's Gross Profit is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Verona Pharma's earnings, one of the primary drivers of an investment's value.

Verona Current Valuation vs. Competition

Verona Pharma PLC is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 230.24 Billion. Verona Pharma claims roughly 3.06 Billion in current valuation contributing just under 2% to equities under Health Care industry.

Verona Gross Profit vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Verona Pharma

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
3.06 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Verona Pharma

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
112 K
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Verona Gross Profit Comparison

Verona Pharma is currently under evaluation in gross profit category among its peers.

Verona Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Verona Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Verona Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Verona Pharma's change in net profit over the period of time. It can combine multiple indicators of Verona Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4.1 M-3.9 M
Operating Income-67.8 M-64.4 M
Income Before Tax-55.2 M-52.5 M
Total Other Income Expense Net12.6 M13.2 M
Net Loss-54.6 M-51.9 M
Income Tax Expense-632.4 K-664.1 K
Net Loss-50.7 M-48.2 M
Net Loss-61.8 M-58.7 M
Interest Income11.3 M11.9 M
Net Interest Income9.7 M10.2 M
Change To Netincome21.7 M22.8 M
Net Loss(0.69)(0.72)
Income Quality 0.92  0.62 
Net Income Per E B T 0.98  0.73 

Verona Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Verona Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Verona Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Verona Pharma's important profitability drivers and their relationship over time.

Use Verona Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Verona Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Verona Pharma will appreciate offsetting losses from the drop in the long position's value.

Verona Pharma Pair Trading

Verona Pharma PLC Pair Trading Analysis

The ability to find closely correlated positions to Verona Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Verona Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Verona Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Verona Pharma PLC to buy it.
The correlation of Verona Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Verona Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Verona Pharma PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Verona Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Verona Pharma position

In addition to having Verona Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Blend Funds Thematic Idea Now

Small Blend Funds
Small Blend Funds Theme
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:
Check out World Market Map.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
To fully project Verona Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Verona Pharma PLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Verona Pharma's income statement, its balance sheet, and the statement of cash flows.
Potential Verona Pharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Verona Pharma investors may work on each financial statement separately, they are all related. The changes in Verona Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Verona Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.